ES2173869T3 - Metodo de tratamiento de enfermedad pulmonar con trifosfatos de uridina. - Google Patents

Metodo de tratamiento de enfermedad pulmonar con trifosfatos de uridina.

Info

Publication number
ES2173869T3
ES2173869T3 ES92922217T ES92922217T ES2173869T3 ES 2173869 T3 ES2173869 T3 ES 2173869T3 ES 92922217 T ES92922217 T ES 92922217T ES 92922217 T ES92922217 T ES 92922217T ES 2173869 T3 ES2173869 T3 ES 2173869T3
Authority
ES
Spain
Prior art keywords
uridine
tryphosphates
treatment method
pulmonary disease
lungs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92922217T
Other languages
English (en)
Inventor
Richard C Boucher Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
University of North Carolina System
Original Assignee
University of North Carolina at Chapel Hill
University of North Carolina System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill, University of North Carolina System filed Critical University of North Carolina at Chapel Hill
Application granted granted Critical
Publication of ES2173869T3 publication Critical patent/ES2173869T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCRIBE UN METODO PARA HIDRATAR SECRECIONES MUCOSAS EN LOS PULMONES DE UN SUJETO CON NECESIDAD DE TAL TRATAMIENTO. EL METODO CONSISTE EN LA ADMINISTRACION A LOS PULMONES DEL SUJETO DE TRISFOSFATO DE URIDINA TAL COMO 5''-TRIFOSFATO DE URIDINA (UTP) O 5''O-(3-TIOTRIFOSFATO) DE URIDINA (UTPGAMMAS) EN UNA CANTIDAD EFECTIVA PARA HIDRATAR SECRECIONES MUCOSAS DEL PULMON. EL METODO ES UTIL PARA TRATAR PACIENTES AFLIGIDOS DE FIBROSIS CISTICA. TAMBIEN SE DESCRIBEN FORMULACIONES FARMACEUTICAS Y METODOS PARA ELABORARLAS.
ES92922217T 1991-06-19 1992-10-09 Metodo de tratamiento de enfermedad pulmonar con trifosfatos de uridina. Expired - Lifetime ES2173869T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/717,747 US5292498A (en) 1991-06-19 1991-06-19 Method of treating lung disease with uridine triphosphates
PCT/US1992/008620 WO1994008593A1 (en) 1991-06-19 1992-10-09 Method of treating lung disease with uridine triphosphates

Publications (1)

Publication Number Publication Date
ES2173869T3 true ES2173869T3 (es) 2002-11-01

Family

ID=26785072

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92922217T Expired - Lifetime ES2173869T3 (es) 1991-06-19 1992-10-09 Metodo de tratamiento de enfermedad pulmonar con trifosfatos de uridina.

Country Status (8)

Country Link
US (1) US5292498A (es)
EP (1) EP0663830B1 (es)
JP (1) JPH08502078A (es)
AU (1) AU688258B2 (es)
DE (1) DE69232565T2 (es)
ES (1) ES2173869T3 (es)
NO (1) NO309176B1 (es)
WO (1) WO1994008593A1 (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005779A1 (en) * 1990-10-05 1992-04-16 The University Of North Carolina At Chapel Hill Method of administering amiloride
EP0517573A1 (fr) * 1991-06-05 1992-12-09 Synthelabo Compositions pharmaceutiques pour le traitement des affections des voies respiratoires
US5512269A (en) * 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
US5514665A (en) * 1993-12-30 1996-05-07 University Of British Columbia Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans
US6204382B1 (en) 1994-08-05 2001-03-20 Cytec Technology Corp. Carboxylated amino-1,3,5-triazines, derivatives thereof and processes for preparing the same
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US20030032614A1 (en) * 1995-04-13 2003-02-13 Mcmichael John Method of treating respiratory distress using synthetic polynucleic acids
US5948768A (en) * 1995-04-13 1999-09-07 Milkhaus Laboratory Treatment of otitis media by sublingual administration of DNA
US20020115632A1 (en) * 1995-04-13 2002-08-22 Milkhaus Laboratory, Inc. Treatment of symptoms of asthma and allergies
US6096721A (en) * 1995-04-13 2000-08-01 Milkhaus Laboratory, Inc. Method for treating mucositis by sublingual administration of DNA
EP0766570B1 (en) * 1995-04-13 2001-12-12 Milkhaus Laboratory, Inc. Methods for treating respiratory disease
US5908611A (en) * 1995-05-05 1999-06-01 The Scripps Research Institute Treatment of viscous mucous-associated diseases
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US6423694B1 (en) * 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
US6673779B2 (en) * 1996-03-27 2004-01-06 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with dinucleoside polyphosphate compounds or UTP analogues
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US6420347B1 (en) * 1997-03-27 2002-07-16 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
CN1229114C (zh) * 1996-03-27 2005-11-30 印斯拜尔药品股份有限公司 用三磷酸尿苷和相关化合物治疗纤毛运动障碍的方法
US5968913A (en) * 1996-07-03 1999-10-19 Inspire Pharmaceuticals, Inc. Pharmaceutical compositions of uridine triphosphate
US5789391A (en) * 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US5962432A (en) * 1996-07-03 1999-10-05 Inspire Pharmaceuticals, Inc. Sterilized, isotonic and pH-adjusted pharmaceutical formulation of uridine triphosphate
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) * 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6159952A (en) * 1996-11-07 2000-12-12 Inspire Pharmaceuticals, Inc. Method of treating bronchitis with uridine triphosphate and related compounds
US6696425B2 (en) * 1997-02-06 2004-02-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
US6921755B2 (en) * 1998-02-06 2005-07-26 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
CN1262556C (zh) * 1997-02-06 2006-07-05 印斯拜尔药品股份有限公司 特定的二核苷酸和它们作为粘膜纤毛清除和纤毛颤动频率调节剂的应用
US6998121B2 (en) * 2003-01-23 2006-02-14 Milkhaus Laboratory, Inc. Method of treatment of connective tissue disorders by administration of streptolysin O
KR20010013797A (ko) 1997-07-25 2001-02-26 인스파이어 파마슈티컬스 인코퍼레이티드 디(우리딘 5'-테트라포스페이트) 염 및 그의 제조방법과용도
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
US6143279A (en) * 1997-08-29 2000-11-07 The University Of North Carolina At Chapel Hill Uridine 5'-diphosphate and analogs useful for treating lung diseases
ATE232733T1 (de) 1998-05-22 2003-03-15 Inspire Pharmaceuticals Inc Therapeutische dinucleotide und deren derivate
US6294188B1 (en) 1998-07-09 2001-09-25 Aviana Biopharm Inc. Methods involving changing the constitutive and stimulated secretions of the local reproductive system of women
WO2000036915A1 (en) 1998-12-22 2000-06-29 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
US7544772B2 (en) * 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US8501911B2 (en) * 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
JP4969002B2 (ja) * 1999-06-08 2012-07-04 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン ｒＡＡＶ形質導入を増加するための化合物および方法
EP1196396B1 (en) 1999-07-19 2008-03-26 University Of North Carolina At Chapel Hill Pharmacologically active compounds with two covalently linked active principles (sodium channnel blocker/p2y2 receptor agonist) for the treatment of mucosal surfaces
US7241447B1 (en) * 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
CA2413928C (en) * 2000-05-30 2011-01-25 Santen Pharmaceutical Co., Ltd. Corneal epithelial migration promoter
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US6555675B2 (en) * 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
US7115585B2 (en) * 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
WO2002062816A1 (en) * 2001-02-07 2002-08-15 Celltech R & D Limited Non-natural nucleotides and dinucleotides
US7109181B2 (en) 2001-06-25 2006-09-19 Inspire Pharmaceuticals, Inc. Joint lubrication with P2Y purinergic receptor agonists
PT1411967E (pt) * 2001-06-26 2011-09-30 Univ North Carolina State Péptido bloqueador que atua sobre a secreção de células inflamatórias
WO2003011885A1 (en) * 2001-07-25 2003-02-13 Celltech R & D Limited Non-natural carbon-linked nucleotides and dinucleotides
US7256183B2 (en) * 2001-11-06 2007-08-14 Inspire Pharmaceuticals, Inc. Method for treating or preventing inflammatory diseases
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
US20100144602A1 (en) * 2003-01-23 2010-06-10 Milkhaus Laboratory, Inc. Methods of Inhibiting Metastatic Cancer by Administration of Streptolysin O
US7629312B2 (en) 2003-01-23 2009-12-08 Milkhaus Laboratory, Inc. Method of treatment of tendonitis by administration of streptolysin O
US7749491B2 (en) * 2003-03-31 2010-07-06 University Of Iowa Research Foundation Compounds and methods to enhance rAAV transduction
CA2534682C (en) 2003-08-18 2013-02-26 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
US20090253714A1 (en) * 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
CN101146545B (zh) * 2005-01-20 2012-12-26 拜欧马克医药有限公司 基于mans的结构的粘蛋白分泌过多抑制剂和应用方法
US7851456B2 (en) * 2005-06-29 2010-12-14 Inspire Pharmaceuticals, Inc. P2Y6 receptor agonists for treating lung diseases
US20070021439A1 (en) * 2005-07-25 2007-01-25 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers
EP2036567A3 (en) 2005-12-06 2009-12-09 P2-Science APS Modulation of the P2Y2 receptor pathway
US20080182789A1 (en) * 2007-01-30 2008-07-31 Milkhaus Laboratory, Inc. Method of treating pulmonary fibrosis
CA2651180A1 (en) * 2006-04-28 2007-11-08 University Of Iowa Research Foundation Methods and compounds to alter virus infection
AU2007279193B2 (en) 2006-07-26 2011-12-01 Biomarck Pharmaceuticals, Ltd. Methods for attenuating release of inflammatory mediators and peptides useful therein
US8551534B2 (en) * 2007-10-10 2013-10-08 Parion Sciences, Inc. Inhaled hypertonic saline delivered by a heated nasal cannula
JP5611844B2 (ja) 2008-02-26 2014-10-22 パリオン・サイエンシィズ・インコーポレーテッド 多環芳香族ナトリウムチャネル遮断薬
AU2010283742A1 (en) 2009-08-10 2012-03-29 P2-Science Aps UTP for the diagnosis of stenoses and other conditions of restricted blood flow
CN103328038A (zh) 2010-12-01 2013-09-25 史拜诺莫度雷森公司 向神经解剖结构直接递送药剂
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
EP2717855A4 (en) 2011-06-07 2014-11-12 Parion Sciences Inc PROCESSING METHODS
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
CA2839709C (en) 2011-06-27 2020-01-14 Parion Sciences, Inc. A chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
US9603906B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Inhalable liquid formulations of DNase I
PT2855435T (pt) 2012-05-29 2018-07-03 Parion Sciences Inc Aminoamidas do tipo dendrímeros possuindo atividade bloqueadora de canais de sódio para o tratamento do olho seco e outras doenças das mucosas
KR20150095870A (ko) 2012-12-17 2015-08-21 패리온 사이언스 인코퍼레이티드 3,5-디아미노-6-클로로-n-(n-(4-페닐부틸)카르밤이미도일)피라진-2-카르복스아미드 화합물
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
EP3150585A1 (en) 2012-12-17 2017-04-05 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
MA43735A (fr) 2016-03-07 2018-11-28 Univ Iowa Res Found Expression médiée par aav utilisant un promoteur et un activateur synthétiques
WO2018132747A1 (en) 2017-01-13 2018-07-19 University Of Iowa Research Foundation Bocaparvovirus small noncoding rna and uses thereof
US20230158125A1 (en) 2020-04-20 2023-05-25 Sorrento Therapeutics, Inc. Pulmonary Administration of ACE2 Polypeptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
JPS60126220A (ja) * 1983-12-09 1985-07-05 Otsuka Pharmaceut Factory Inc 核酸成分組成物
US5100647A (en) * 1990-10-02 1992-03-31 The Trustees Of The University Of Pennsylvania Method and formulations for the therapy of cystic fibrosis, Bartter's syndrome and secretory diarrheas, and for diuretic treatment
GB9027968D0 (en) * 1990-12-22 1991-02-13 Fisons Plc Method of treatment

Also Published As

Publication number Publication date
NO951340D0 (no) 1995-04-06
DE69232565T2 (de) 2002-11-14
DE69232565D1 (de) 2002-05-23
NO309176B1 (no) 2000-12-27
EP0663830A1 (en) 1995-07-26
NO951340L (no) 1995-06-02
JPH08502078A (ja) 1996-03-05
WO1994008593A1 (en) 1994-04-28
US5292498A (en) 1994-03-08
EP0663830A4 (en) 1996-01-24
EP0663830B1 (en) 2002-04-17
AU688258B2 (en) 1998-03-12
AU2872592A (en) 1994-05-09

Similar Documents

Publication Publication Date Title
ES2173869T3 (es) Metodo de tratamiento de enfermedad pulmonar con trifosfatos de uridina.
MX9709637A (es) Dinucleotidos utiles para el tratamiento de enfermedades pulmonares.
US5958897A (en) Method of treating sinusitis with uridine triphosphates and related compounds
US5763447C1 (en) Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
EP0841900A4 (es)
ATE225663T1 (de) Verfahren zur behandlung von mittelohrentzündung mittels uridintriphosphaten und verwandten mitteln
ES2093130T3 (es) Forma de ciclosporin para administracion pulmonar.
IL141494A0 (en) Stable hypoxia inducible factor-1 alpha and method of use
ITFI910296A0 (it) Laringoscopio basculante a spatula ricurva motorizzata, particolarmente per praticare l' intubazione di pazienti sotto anestesia o rianimazione
YU94089A (en) Process for preparing cyclopentan analogs of purine nucleotides
Clerf Bronchoscopy as an aid in diagnosis and treatment of bronchial asthma
EA200000686A1 (ru) Препараты левозимендана, предназначенные для введения через слизистую оболочку
Gupta et al. Leprosy of the larynx. A clinicopathological study
ES2111013T3 (es) Una composicion profilactica/terapeutica que contiene ws7622a para evitar o tratar la coagulacion intravascular diseminada, la enfermedad infecciosa cronica del tracto respiratorio o la bronquitis cronica.
Briggs et al. Tracheotomy in acute obliterative laryngotracheobronchitis
CLASS et al. Spontaneous tension pneumomediastinum complicating pulmonary tuberculosis
Lal et al. Chromomycosis caused by Exophiala jeanselmei
NO952212D0 (no) Preparater inneholdende acyclovirlignende forbindelser og 2'-vinylsubstituerte nukleosidanaloger for behandling av virale infeksjoner
UA30945A (uk) Спосіб лікування вірусної інфекції шкіри та слизових оболонок

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 663830

Country of ref document: ES